Orano Med
Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).
AlphaMedix phase 2 (ORR 56% in SSTR+ NETs), 212Pb generators, partnerships with Sanofi and RadioMedix.
Pages like this
not linked directly; found by shared links- CompanyITM Isotope Technologies Munich
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Somatostatin receptor 2.
- CompanyTerraPower Isotopes
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- ProductActinium-225 DOTATATE
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Somatostatin receptor 2.
- TrialALPHAMEDIX-02
Shares 212Pb-DOTAMTATE, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyPerspective Therapeutics
Shares Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211, Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyRayzeBio (BMS)
Shares Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.